What Not To Do When An FDA Inspector Knocks At Your Door
This article was originally published in The Tan Sheet
Executive Summary
FDA tweaks its guidance on what constitutes interference with inspections to include examples of “reasonable” explanations for delays. But industry requested other changes, including a formal process for notifying a firm of FDA’s intent to deem products adulterated due to delaying, limiting or refusing an inspection.
You may also be interested in...
Rx Companies Push For Exemptions To Breadth Of FDA Inspections
Sterile areas, cell therapies, and security systems are just a few of the items where industry wants FDA inspector access limited without triggering a new law that would make products in a facility deemed adulterated.
Building On Successes During Turbulent Times, SR One Closes $600m Fund II
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.
Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.